Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based Taiho Pharmaceutical has released results from a double-blind, randomized, placebo-controlled Phase II clinical trial of TAS-102 for the patients with metastatic colorectal cancer.
Subscribe to our email newsletter
The results of the trial suggested that the drug showed improvement in overall survival as comparison to placebo and has also demonstrated reduction in risk of mortality.
The trial evaluated around 172 patients with refractory metastatic colorectal cancer who had received standard chemotherapy at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin.